Phase 3 Study Comparing Preventive Versus Early Use of Entecavir in Patients With Gastrointestinal Cancer and Inactive Hepatitis B During Chemotherapy or Immunotherapy
Led by Sun Yat-sen University · Updated on 2025-05-11
136
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of two different strategies for using the antiviral drug entecavir in patients with gastrointestinal cancers who are also inactive carriers of hepatitis B virus. This phase 3, open, multicenter, randomized controlled trial aims to compare prophylactic use versus preemptive use of entecavir during chemotherapy or immunotherapy and subsequent follow-up periods. The study addresses an important question since it is currently unclear whether inactive hepatitis B carriers with gastrointestinal cancer should receive entecavir preventively or only if viral reactivation occurs during anti-tumor treatment.
Participants are assigned to one of two groups. The experimental group receives entecavir at 0.5 mg orally every day starting from the beginning of chemotherapy or immunotherapy and continuing until 6 months after treatment ends. The comparator group receives entecavir at the same dose only if hepatitis B virus DNA becomes detectable during treatment, continuing for 6 months after therapy completion. This design includes two cohorts receiving chemotherapy or immunotherapy, enabling comparison of antiviral strategies alongside different anti-tumor therapies.
During the study, patients undergo regular monitoring for hepatitis B virus reactivation and liver function over an average follow-up of one year. Researchers assess the incidence of viral reactivation as the primary outcome, along with secondary outcomes such as hepatitis occurrence, interruption of anti-tumor therapy due to hepatitis, severe HBV-related hepatitis, acute liver failure, and related deaths. Patients are closely followed for safety and treatment adherence throughout chemotherapy or immunotherapy and the 6-month post-treatment period, with laboratory tests and clinical evaluations conducted at scheduled intervals.
CONDITIONS
Brief Title
Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers
Research Team
X
Xu Rui-hua, M.D. Ph.D
W
Wang Feng, M.D. Ph.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Planned to receive first-, second-, or third-line chemotherapy or PD-1/PD-L1 immunotherapy
Eastern Cooperative Oncology Group performance status (ECOG) 0-2
Planned for at least 4 cycles of chemotherapy or immunotherapy
Life expectancy of at least 6 months from recruitment
Chronic or past hepatitis B infection with inactive hepatitis (HBsAg-positive or HBcAb-positive)
Normal liver function tests (ALT, AST, bilirubin)
Negative HBV-DNA test
Adequate major organ function within 14 days before randomization
Signed informed consent
Good compliance during chemotherapy and follow-ups
You will not qualify if you...
History of liver cirrhosis
Prior hepatitis B virus reactivation
Anti-HBV therapy for chronic hepatitis B within 6 months before enrollment
Active co-infection with other hepatitis viruses
HIV infection
Autoimmune hepatitis
History or scheduled hepatic radiotherapy or radioisotope therapy
Pregnant or lactating women
History of psychiatric drug abuse or mental disorder preventing quitting
Immunodeficiency, congenital or acquired, or transplantation history
Any concomitant disease judged by investigators to seriously harm safety or study completion
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - From initiation of chemotherapy or immunotherapy until 6 months after treatment ends
Participants receive entecavir either prophylactically from the start of chemotherapy or immunotherapy, or preemptively if hepatitis B virus DNA becomes positive. Treatment continues daily until 6 months after the end of chemotherapy or immunotherapy.
Visits occur according to chemotherapy or immunotherapy schedule
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Prospective Multicenter Study on Digestive Tract Cancer Screening Using Combined Blood Multi-Gene Methylation and Fecal Biomarkers
Feasibility Study of Social Needs Screening and Referral for Cancer Survivors in Metro Detroit
Study of Electroacupuncture and Self-administered Acupressure to Prevent Hand-Foot Syndrome in Adults Taking Capecitabine for Cancer
Study of New HyperSight CBCT Imaging for Guiding Radiation Therapy in Adults with Cancer
Study Comparing Three Pain Management Methods During Minimally Invasive Cancer Surgery
Using Laparoscopic Transversus Abdominis Plane Block and Local Anesthetic
Randomized Study Comparing Personalized RISE Self-Management Training to Standardized Training for Gastrointestinal Cancer Patients
Open-Label Phase 12 Study of Intravenous BHB810 for Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Dose Escalation and Expansion
Phase 3 Study Comparing Preventive Versus Early Use of Entecavir in Patients With Gastrointestinal Cancer and Inactive Hepatitis B During Chemotherapy or Immunotherapy
Pilot Study of CYTALUX Pafolacianine Injection to Help Detect Cancer During Surgery for Gastrointestinal, Esophageal, Pancreatic, Hepatobiliary, and Gynecologic Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.
Robert P Perrillo, Robert Gish, Yngve T Falck-Ytter
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.